Prostate Cancer Early Detection Articles & Analysis
10 news found
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for ...
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona Urology, a comprehensive urological care center with three physician offices in the surrounding Phoenix area. Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in-person in ...
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee. Novosanis hereby offers a solution for applications in the field of oncology research and ...
Lightpoint Medical, a leading medical device company developing and marketing innovative technologies for intra-operative cancer detection, announced clinical trial results today to support the use of the company's miniature surgical gamma probe, SENSEI®, in prostate sentinel lymph node detection. The interim results from the multi-center clinical trial, which involves cancer centers at ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
"The high incidence of mortality among Puerto Rican men due to prostate cancer on the island is of great concern to all of us. It is time to take concrete action and join forces to educate our men about the importance of screening and early detection for prostate cancer," Governor Pedro Pierluisi ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland ...
Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics for the detection of cancers, today announced the online publication of interim results for an ongoing multi-center trial of the IsoPSA™ prostate cancer test in European Urology. The findings illustrate a significantly ...